
Processa Pharmaceuticals PCSA
$ 2.42
8.04%
Annual report 2025
added 03-18-2026
Processa Pharmaceuticals Long Term Debt Current 2011-2026 | PCSA
Annual Long Term Debt Current Processa Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 83.6 K | 78.9 K | 71.1 K | 87.2 K | 78 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 87.2 K | 71.1 K | 79.8 K |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Ultragenyx Pharmaceutical
RARE
|
12 M | $ 19.23 | -3.85 % | $ 1.9 B | ||
|
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | ||
|
RedHill Biopharma Ltd.
RDHL
|
353 K | $ 0.8 | 0.89 % | $ 428 M | ||
|
Regeneron Pharmaceuticals
REGN
|
37.8 M | $ 742.02 | -1.94 % | $ 77.6 B | ||
|
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
410 K | - | 1.93 % | $ 17.4 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | ||
|
Replimune Group
REPL
|
1.18 M | $ 7.22 | -4.24 % | $ 582 M | ||
|
REGENXBIO
RGNX
|
8.29 M | $ 7.88 | -4.6 % | $ 406 M | ||
|
Aileron Therapeutics
ALRN
|
48 K | - | 10.36 % | $ 9.8 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Rigel Pharmaceuticals
RIGL
|
614 K | $ 26.2 | -0.64 % | $ 471 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
Atreca
BCEL
|
3.54 M | - | -11.76 % | $ 5.79 M | ||
|
Avidity Biosciences
RNA
|
3.94 M | $ 13.09 | -0.08 % | $ 1.8 B | ||
|
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | ||
|
bluebird bio
BLUE
|
21.2 M | - | - | $ 546 M | ||
|
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | ||
|
Avid Bioservices
CDMO
|
1.35 M | - | - | $ 789 M | ||
|
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Rhythm Pharmaceuticals
RYTM
|
650 K | $ 78.52 | -4.13 % | $ 5.1 B | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
8.92 M | $ 12.57 | -9.96 % | $ 1.91 B | ||
|
Sana Biotechnology
SANA
|
14.9 M | $ 2.78 | -8.42 % | $ 704 M | ||
|
BeiGene, Ltd.
BGNE
|
20.7 M | - | 0.49 % | $ 251 B | ||
|
SIGA Technologies
SIGA
|
595 K | $ 5.35 | 7.76 % | $ 383 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
45.5 M | $ 321.71 | -1.96 % | $ 42.1 B | ||
|
Cara Therapeutics
CARA
|
1.92 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
2.81 M | - | - | $ 3.74 B | ||
|
Silence Therapeutics plc
SLN
|
179 K | $ 4.8 | -9.6 % | $ 622 M | ||
|
Enochian Biosciences
ENOB
|
313 K | - | - | $ 40.5 M |